ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

telitacicept

Also written as “Telitacicept”, “RC18 160mg” and “RC18 240mg”.

Its studies are mostly in Lupus Erythematosus, Systemic · Glomerulonephritis, IGA · Myasthenia Gravis · Sjogren's Syndrome · Lymphoma, Follicular, led by 3 companies.

Drug pageTelitacicept: every studyAll 54 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 8, 201725 company-led studies, 8 open or runningNext primary completion: Dec 31, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
RemeGen194 open or runningphase 3since Jan 8, 2017Aug 24, 2016Dec 31, 2026phase 3 · NCT07249632
Vor Biopharmaits history only42 open or runningphase 3since Mar 23, 2022Mar 23, 2022Mar 2027phase 3 · NCT06456580
Innovent Biologicsits history only22 open or runningphase 2since Sep 13, 2026Sep 13, 2026Jan 31, 2027phase 1 · NCT07886476

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of RemeGen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 5 earlier studies, Aug 24, 2016 to Jul 18, 2019.

  1. Dec 9, 2018Named telitaciceptINNProposed as its International Nonproprietary Name in WHO's List 120
  2. Sep 1, 2019Phase 3 study in Lupus Erythematosus, SystemicNCT04082416 · 335 enrolled · China
  3. Jan 6, 2020Phase 1 study in HealthyNCT04235933 · 36 enrolled · China
  4. Feb 27, 2020Phase 2 study in Glomerulonephritis, IGANCT04291781 · 44 enrolled · China
  5. Mar 6, 2020Phase 2 study in Systemic Myasthenia GravisNCT04302103 · 29 enrolled · China
  6. Nov 6, 2020Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT04625153 · 8 enrolled · China
  7. May 21, 2021Phase 2 study in Glomerulonephritis, IGANCT04905212 · 15 enrolled · United States
  8. Jan 26, 2022Phase 1 study in Lupus Erythematosus, SystemicNCT05247203 · 92 enrolled · China
  9. Dec 26, 2022Phase 2 study in Lupus NephritisNCT05680480 · 120 planned · China
  10. Dec 29, 2022Phase 3 study in Primary Sjogren's SyndromeNCT05673993 · 381 enrolled · China
  11. Jan 8, 2023Phase 1 study in Lupus Erythematosus, SystemicNCT05687526 · 16 enrolled · China
  12. Feb 12, 2023Phase 3 study in Myasthenia GravisNCT05737160 · 114 enrolled · China
  13. Mar 5, 2023Phase 3 study in Glomerulonephritis, IGANCT05799287 · 318 enrolled · China
  14. Nov 18, 2025Phase 3 study in Myasthenia GravisNCT07249632 · 120 planned · China
  15. Mar 9, 2026Phase 3 study in CTD-ILDNCT07495033 · 260 planned · China

Ahead

  1. Dec 31, 2026Primary completion: phase 3 study in Myasthenia GravisNCT07249632
  2. May 31, 2029Primary completion: phase 3 study in CTD-ILDNCT07495033

TargetBeta

TNFRSF13B →read by rule
“A fusion protein composed of the extracellular domain of human tumor necrosis factor receptor superfamily member 13B (TNFRSF13B; transmembrane activator and calcium modulator and cyclophilin ligand interactor; TACI) ”NCIt, by rule

Other programs on TNFRSF13B

ProgramCompanyFurthest phaseStudies
povetaciceptruleVertex Pharmaceuticalsphase 39
SHR-2173Jiangsu HengRui Medicinephase 28

Studies

All 19 RemeGen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07495033CTD-ILD · China3Not yet recruitingMay 31, 2029260
NCT07249632Myasthenia Gravis · China3RecruitingDec 31, 2026120
NCT05799287Glomerulonephritis, IGA · China3Active, not recruitingJun 2026318
NCT05737160Myasthenia Gravis · China3CompletedNov 26, 2024114
NCT05687526Lupus Erythematosus, Systemic · China1CompletedNov 14, 202516
NCT05673993Primary Sjogren's Syndrome · China3CompletedOct 29, 2024381
NCT05680480Lupus Nephritis · China2RecruitingDec 2025120
NCT05247203Lupus Erythematosus, Systemic · China1CompletedOct 25, 202392
NCT04905212Glomerulonephritis, IGA · United States2TerminatedNov 9, 202315
NCT04625153Multiple Sclerosis, Relapsing-Remitting · China2TerminatedApr 3, 20268
NCT04302103Systemic Myasthenia Gravis · China2CompletedJan 14, 202229
NCT04291781Glomerulonephritis, IGA · China2CompletedMay 20, 202144
NCT04235933Healthy · China1CompletedDec 20, 201936
NCT04082416Lupus Erythematosus, Systemic · China3CompletedApr 24, 2022335
NCT04078386Primary Sjögren's Syndrome · China2CompletedJun 23, 202142
NCT03330418Neuromyelitis Optica · China3TerminatedApr 3, 2026178
NCT03016013Lymphoma, Follicular · China3CompletedNov 19, 2022479
NCT02885610Lupus Erythematosus, Systemic · China2CompletedJun 11, 2019249
NCT02882087Lymphoma, Follicular · China2TerminatedFeb 25, 201960

How it is read

Names in the registry

  • “Telitacicept”, 11 entries
  • “RC18 160mg”, 3 entries
  • “RC18 240mg”, 3 entries
  • “RC18 240 mg”, 2 entries
  • “RC18 160 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.